Free public records show Sarepta Theraps Inc in 1 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
3 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Sarepta Theraps Inc: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Sarepta Theraps Inc is in.
Stories on the topics Sarepta Theraps Inc works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Read